PMV Pharmaceuticals (PMVP) Competitors $1.37 +0.10 (+7.56%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMVP vs. TVRD, ZYBT, CRDF, MREO, KOD, MNPR, TSVT, AARD, PRQR, and INZYShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Tvardi Therapeutics (TVRD), Zhengye Biotechnology (ZYBT), Cardiff Oncology (CRDF), Mereo BioPharma Group (MREO), Kodiak Sciences (KOD), Monopar Therapeutics (MNPR), 2seventy bio (TSVT), Aardvark Therapeutics (AARD), ProQR Therapeutics (PRQR), and Inozyme Pharma (INZY). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. Its Competitors Tvardi Therapeutics Zhengye Biotechnology Cardiff Oncology Mereo BioPharma Group Kodiak Sciences Monopar Therapeutics 2seventy bio Aardvark Therapeutics ProQR Therapeutics Inozyme Pharma PMV Pharmaceuticals (NASDAQ:PMVP) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Which has more risk & volatility, PMVP or TVRD? PMV Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Which has higher valuation & earnings, PMVP or TVRD? PMV Pharmaceuticals has higher earnings, but lower revenue than Tvardi Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPMV PharmaceuticalsN/AN/A-$58.71M-$1.18-1.16Tvardi Therapeutics$7.14M36.40-$70.87MN/AN/A Do insiders & institutionals hold more shares of PMVP or TVRD? 90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to PMVP or TVRD? In the previous week, Tvardi Therapeutics' average media sentiment score of 1.11 beat PMV Pharmaceuticals' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment PMV Pharmaceuticals Neutral Tvardi Therapeutics Positive Is PMVP or TVRD more profitable? PMV Pharmaceuticals has a net margin of 0.00% compared to Tvardi Therapeutics' net margin of -595.39%. PMV Pharmaceuticals' return on equity of -32.54% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PMV PharmaceuticalsN/A -32.54% -29.59% Tvardi Therapeutics -595.39%-710.04%-79.00% Do analysts recommend PMVP or TVRD? PMV Pharmaceuticals presently has a consensus price target of $5.50, suggesting a potential upside of 302.64%. Tvardi Therapeutics has a consensus price target of $64.25, suggesting a potential upside of 131.36%. Given PMV Pharmaceuticals' higher possible upside, equities analysts plainly believe PMV Pharmaceuticals is more favorable than Tvardi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPMV Pharmaceuticals beats Tvardi Therapeutics on 8 of the 11 factors compared between the two stocks. Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.18M$2.49B$5.63B$9.41BDividend YieldN/A1.80%4.01%4.02%P/E Ratio-1.169.2328.4320.05Price / SalesN/A589.75415.6587.96Price / CashN/A165.2635.9658.29Price / Book0.405.178.525.82Net Income-$58.71M$30.99M$3.24B$258.18M7 Day Performance1.94%4.34%4.58%3.68%1 Month Performance27.66%15.65%12.60%14.51%1 Year Performance-15.16%-0.35%35.87%19.00% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals2.4697 of 5 stars$1.37+7.6%$5.50+302.6%-19.6%$71.18MN/A-1.1650Gap UpTVRDTvardi TherapeuticsN/A$29.83+9.1%$64.25+115.4%N/A$279.21M$7.14M0.0080Gap UpHigh Trading VolumeZYBTZhengye BiotechnologyN/A$5.87-0.3%N/AN/A$276.86M$186.36M0.00278Gap UpCRDFCardiff Oncology0.927 of 5 stars$4.13+1.5%$11.70+183.3%+60.9%$274.77M$680K-4.4920MREOMereo BioPharma Group1.683 of 5 stars$1.72+6.8%$7.20+318.6%-55.8%$273.48M$10M-24.5740High Trading VolumeKODKodiak Sciences3.6293 of 5 stars$5.17+14.1%$9.00+74.1%+86.6%$272.77MN/A-1.4290Gap UpMNPRMonopar Therapeutics2.4309 of 5 stars$43.73+18.6%$60.00+37.2%+1,324.3%$267.63MN/A-12.5710TSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440AARDAardvark TherapeuticsN/A$12.11-0.5%$33.00+172.5%N/A$262.74MN/A0.0018Gap UpPRQRProQR Therapeutics2.1527 of 5 stars$2.48+6.9%$8.00+222.6%+26.7%$260.92M$20.46M-7.09180INZYInozyme Pharma2.8731 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750Positive News Related Companies and Tools Related Companies Tvardi Therapeutics Alternatives Zhengye Biotechnology Alternatives Cardiff Oncology Alternatives Mereo BioPharma Group Alternatives Kodiak Sciences Alternatives Monopar Therapeutics Alternatives 2seventy bio Alternatives Aardvark Therapeutics Alternatives ProQR Therapeutics Alternatives Inozyme Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMVP) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMVP Stock Alerts